For Research Use Only

## CoraLite® Plus 488-conjugated FABP5 Polyclonal antibody



**Purification Method:** 

Catalog Number: CL488-12348

Featured Product

**Basic Information** 

Catalog Number: GenBank Accession Number:

CL488-12348 BC019385 Antigen affinity purification GeneID (NCBI): Recommended Dilutions: 100ul, Concentration: 1000 ug/ml by 2171 IF/ICC 1:50-1:500

Nanodrop: **UNIPROT ID:** Excitation/Emission maxima

Q01469 wavelengths: Rabbit 493 nm / 522 nm Full Name:

Isotype: fatty acid binding protein 5 (psoriasisassociated)

IgG Immunogen Catalog Number: Calculated MW: 135 aa, 15 kDa AG3005

Observed MW: 15 kDa

**Applications** 

**Tested Applications:** Positive Controls: IF/ICC, FC (Intra) IF/ICC: HeLa cells,

Species Specificity: human, mouse, rat

## **Background Information**

FABP5, also named as PA-FABP and E-FABP, belongs to the calycin superfamily and Fatty-acid binding protein (FABP) family. It is high specificity for fatty acids. FABP5 is highest affinity for C18 chain length. It may be involved in keratinocyte differentiation. FABP5 is a fatty acid-binding protein and is expressed in epidermis and endothelial cells of the microvasculature of different organs. FABP5 has also been identified as a tumor-associated antigen, which is highly expressed in various cancers. FABP5 was detected in the sera of HNSCC patients with early stage  $cancer. \, Antibodies \, specific \, for \, FABP5 \, were \, significantly \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, a \, substantial \, amount \, in \, patients, \, suggesting \, increased \, in \, substantial \, amount \, in \, patients, \, suggesting \, in \, substantial \, amount \, in \, patients, \, suggesting \, in \, substantial \, amount \, in \, substantial \, amount$ that FABP5 may be a potential diagnostic biomarker for HNSCC. FABP5 may serve as a biomarker for HNSCC. (PMID:19602232)

Storage

Storage:

Store at -20°C. Avoid exposure to light. Stable for one year after shipment.


PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.

Aliquoting is unnecessary for -20°C storage

## Selected Validation Data



Immunofluorescent analysis of (-20°C Ethanol) fixed HeLa cells using CoraLite® Plus 488 FABP5 antibody (CL488-12348) at dilution of 1:200.



1X10^6 HeLa cells were intracellularly stained with 0.4 ug CoraLite® Plus 488 Anti-Human FABP5 (CL488-12348) (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).